INTERVENTIONAL FLASHLIGHT

DOI: 10.4244/EIJ-D-17-00657

Percutaneous intramyocardial septal radiofrequency ablation of hypertrophic obstructive cardiomyopathy: a novel minimally invasive treatment for reduction of outflow tract obstruction

Liwen Liu1*, MD, PhD; Bing Liu2, MD, PhD; Jing Li1, MM; Yanmin Zhang1,3, MD, PhD

Left ventricular outflow tract (LVOT) obstruction occurs in 70% of patients with hypertrophic cardiomyopathy (HCM) and can be associated with disabling symptoms1. Current therapies for drug-refractory symptoms are surgical myectomy2 and alcohol septal ablation (ASA)3. Both procedures improve clinical symptoms and reduce outflow gradients. To take advantage of surgical myectomy and ASA and to avoid sternotomy and damage to the conduction system distributed underneath the endocardium, we proposed a novel procedure (named the Liwen procedure) whereby percutaneous intramyocardial septal radiofrequency ablation is used in the hypertrophic septum to reduce LVOT obstruction.

The Institutional Ethics Committee (KY20162042-1) of Xijing Hospital approved the procedure, which was performed in accordance with the ethical standards of the Declaration of Helsinki. This study was registered at clinicaltrials.gov (NCT02888132). Panels A-C illustrate the Liwen procedure. Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex (Panel D). A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle (17G, Cool-tip™ RF Ablation System and Switching Controller; Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve (Panel E). Each ablation lasts for up to 12 min and the ablation power is gradually increased from 40 to 100 W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS) (Panel F).

A 26-year-old HCM female patient underwent the Liwen procedure. The peak LVOT gradient at rest was 88 mmHg. Although she had taken β-blockers for several years, she had three episodes of syncope and progressive shortness of breath. Both anterior and posterior IVS were ablated 2-3 times with a maximum of 100 W. On cardiac magnetic resonance imaging, a low signal core was present in both anterior and posterior IVS with a thin enhancing rim representing inflamed tissue surrounding the ablated zone three months post procedure, and the zone of ablation showed ongoing fibrosis and shrinkage of the ablation-induced septal lesion six months post procedure (Panel G-Panel I). After six months, her symptoms were significantly relieved and she had no significant complications. With continuously improving LVOT obstruction (Panel J-Panel L), the peak LVOT gradient was reduced to approximately 10 mmHg (Panel M-Panel O).

Conflict of interest statement

The authors have no conflicts of interest to declare.

Volume 13 Number 18
Apr 6, 2018
Volume 13 Number 18
View full issue


Key metrics

On the same subject

Expert review

10.4244/EIJ-D-18-00959 Aug 29, 2019
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a contemporary reappraisal
Pelliccia F et al
free

10.4244/EIJV12SXA1 May 16, 2016
Structural heart interventions: the state of the art and beyond
Feldman T et al
free

INTERVENTIONAL FLASHLIGHT

10.4244/EIJ-D-17-00742 Apr 20, 2018
Alcohol septal ablation preceding transcatheter valve implantation to prevent left ventricular outflow tract obstruction
Sayah N et al
free

10.4244/EIJV15I10A157 Nov 15, 2019
Valvular heart disease: when does surgery remain the best option?
Overtchouk P et al
free
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved